米非司酮与戈舍瑞林用于术后子宫内膜异位症临床疗效及对VEGF的影响

目的探讨米非司酮与戈舍瑞林对于腹腔镜术后子宫内膜异位症(EM)的临床疗效及对血管内皮生长因子(VEGF)的影响。方法将95例患者随机分为3组:米非司酮组34例,术后口服米非司酮;戈舍瑞林组32例,术后皮下注射戈舍瑞林;对照组29例,术后不用药。观察3年内患者复发情况,测定治疗前、术后6月、术后1年患者血清VEGF的变化。结果米非司酮组与戈舍瑞林组3年复发率均低于对照组,差异有统计学意义(P均﹤0.05)。治疗后米非司酮组与戈舍瑞林组血清VEGF下降更为明显,同对照组比较差异均有统计学意义(P均﹤0.05)。结论 EM患者腹腔镜术后应用米非司酮或戈舍瑞林均对防止复发有较好疗效,且能明显降低血清VEGF表达水平。

Study on the clinical effect of mifepristone and goserelin for endometriosis and VEGF

OBJECTIVE To investigate the effects of mifepristone and goserelin after laparoscopic surgery for endometriosis (EM) and vascular endothelial growth factor (VEGF) effects. METHODS 95 patients were randomly divided into 3 groups: mifepristone group (34 patients after oral administration of mifepristone), goserelin group (32 patients with subcutaneous injection of goserelin) and the control group (29 cases with surgery after medication). We observed the recurrence of patients within 3 years, The VEGF in serum were detected before treatment, after 6 months and 1 year after treatment. RESULTS The 3-year recurrence rate of mifepristone group and goserelin group was significantly lower than the control group, and there was significance difference between the two groups (P ﹤ 0.05). After treatment with mifepristone goserelin, VEGF in serum decreased significantly compared with the control group (P﹤0.05). CONCLUSION EM patients with goserelin and mifepristone after laparoscopic or has a good effect on preventing relapse, and can significantly reduce VEGF expression in serum.